Literature DB >> 16421133

Paradoxical response of VEGF expression to hypoxia in CSF of patients with ALS.

C Moreau1, D Devos, V Brunaud-Danel, L Defebvre, T Perez, A Destée, A B Tonnel, Ph Lassalle, N Just.   

Abstract

Vascular endothelial growth factor (VEGF) is implicated in motor neurone degeneration. In normal individuals, hypoxia is known to induce an overexpression of VEGF, as measured in CSF. We show that patients with ALS do not manifest this VEGF overexpression in the presence of hypoxia. Although VEGF gene expression is mainly stimulated by hypoxia, we have measured lower VEGF levels in cerebrospinal fluid (CSF) from hypoxaemic patients with amyotrophic lateral sclerosis (ALS) than in CSF from normoxaemic patients with ALS. In contrast, hypoxaemic neurological controls displayed higher levels than normoxaemic neurological controls. There was a negative correlation between VEGF levels and the severity of hypoxaemia in patients with ALS, suggesting deregulation of VEGF in ALS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16421133      PMCID: PMC2077591          DOI: 10.1136/jnnp.2005.070904

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  14 in total

1.  VEGF is increased in serum but not in spinal cord from patients with amyotrophic lateral sclerosis.

Authors:  Ingela Nygren; Anders Larsson; Anders Johansson; Håkan Askmark
Journal:  Neuroreport       Date:  2002-12-03       Impact factor: 1.837

2.  Daytime predictors of sleep hypoventilation in Duchenne muscular dystrophy.

Authors:  C A Hukins; D R Hillman
Journal:  Am J Respir Crit Care Med       Date:  2000-01       Impact factor: 21.405

3.  Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis.

Authors:  R A Lyall; N Donaldson; M I Polkey; P N Leigh; J Moxham
Journal:  Brain       Date:  2001-10       Impact factor: 13.501

4.  Reduction of a vascular endothelial growth factor receptor, fetal liver kinase-1, by antisense oligonucleotides induces motor neuron death in rat spinal cord exposed to hypoxia.

Authors:  M Shiote; I Nagano; H Ilieva; T Murakami; H Narai; Y Ohta; T Nagata; M Shoji; K Abe
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

5.  Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration.

Authors:  B Oosthuyse; L Moons; E Storkebaum; H Beck; D Nuyens; K Brusselmans; J Van Dorpe; P Hellings; M Gorselink; S Heymans; G Theilmeier; M Dewerchin; V Laudenbach; P Vermylen; H Raat; T Acker; V Vleminckx; L Van Den Bosch; N Cashman; H Fujisawa; M R Drost; R Sciot; F Bruyninckx; D J Hicklin; C Ince; P Gressens; F Lupu; K H Plate; W Robberecht; J M Herbert; D Collen; P Carmeliet
Journal:  Nat Genet       Date:  2001-06       Impact factor: 38.330

6.  Serum levels of vascular endothelial growth factor are elevated in patients with obstructive sleep apnea and severe nighttime hypoxia.

Authors:  Richard Schulz; Christoph Hummel; Sabine Heinemann; Werner Seeger; Friedrich Grimminger
Journal:  Am J Respir Crit Care Med       Date:  2002-01-01       Impact factor: 21.405

7.  Vascular endothelial growth factor prolongs survival in a transgenic mouse model of ALS.

Authors:  Chengyun Zheng; Inger Nennesmo; Bengt Fadeel; Jan-Inge Henter
Journal:  Ann Neurol       Date:  2004-10       Impact factor: 10.422

8.  VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death.

Authors:  Diether Lambrechts; Erik Storkebaum; Masafumi Morimoto; Jurgen Del-Favero; Frederik Desmet; Stefan L Marklund; Sabine Wyns; Vincent Thijs; Jörgen Andersson; Ingrid van Marion; Ammar Al-Chalabi; Stephanie Bornes; Rhiannon Musson; Valerie Hansen; Lars Beckman; Rolf Adolfsson; Hardev Singh Pall; Hervé Prats; Severine Vermeire; Paul Rutgeerts; Shigehiro Katayama; Takuya Awata; Nigel Leigh; Loïc Lang-Lazdunski; Mieke Dewerchin; Christopher Shaw; Lieve Moons; Robert Vlietinck; Karen E Morrison; Wim Robberecht; Christine Van Broeckhoven; Désiré Collen; Peter M Andersen; Peter Carmeliet
Journal:  Nat Genet       Date:  2003-08       Impact factor: 38.330

9.  Effects of vascular endothelial growth factor (VEGF) on motor neuron degeneration.

Authors:  Ludo Van Den Bosch; Erik Storkebaum; Vicky Vleminckx; Lieve Moons; Ludo Vanopdenbosch; Wendy Scheveneels; Peter Carmeliet; Wim Robberecht
Journal:  Neurobiol Dis       Date:  2004-10       Impact factor: 5.996

10.  Cerebrospinal fluid vascular endothelial growth factor in patients with amyotrophic lateral sclerosis.

Authors:  Joanna Iłzecka
Journal:  Clin Neurol Neurosurg       Date:  2004-09       Impact factor: 1.876

View more
  15 in total

1.  Stability analysis of vascular endothelial growth factor in cerebrospinal fluid.

Authors:  Jun Yang; Stephen M Dombrowski; Abhishek Deshpande; Natalie Krajcir; Serge El-Khoury; Chandra Krishnan; Mark G Luciano
Journal:  Neurochem Res       Date:  2011-06-04       Impact factor: 3.996

2.  Amyotrophic lateral sclerosis after embolization of cerebral arterioveneous malformations.

Authors:  Anton Valavanis; Urs Schwarz; Christian R Baumann; Michael Weller; Michael Linnebank
Journal:  J Neurol       Date:  2014-02-08       Impact factor: 4.849

Review 3.  Hypoxia inducible factor-1 as a target for neurodegenerative diseases.

Authors:  Z Zhang; J Yan; Y Chang; S ShiDu Yan; H Shi
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 4.  The application of biomarkers in clinical trials for motor neuron disease.

Authors:  Jeban Ganesalingam; Robert Bowser
Journal:  Biomark Med       Date:  2010-04       Impact factor: 2.851

Review 5.  Stem cell technology for the study and treatment of motor neuron diseases.

Authors:  J Simon Lunn; Stacey A Sakowski; Thais Federici; Jonathan D Glass; Nicholas M Boulis; Eva L Feldman
Journal:  Regen Med       Date:  2011-03       Impact factor: 3.806

6.  Relation between cognitive dysfunction and reduced vital capacity in amyotrophic lateral sclerosis.

Authors:  S-M Kim; K-M Lee; Y-H Hong; K S Park; J-H Yang; H-W Nam; J-J Sung; K-W Lee
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-06-08       Impact factor: 10.154

7.  Gene expression signatures in motor neurone disease fibroblasts reveal dysregulation of metabolism, hypoxia-response and RNA processing functions.

Authors:  Rohini Raman; Scott P Allen; Emily F Goodall; Shelley Kramer; Lize-Linde Ponger; Paul R Heath; Marta Milo; Hannah C Hollinger; Theresa Walsh; J Robin Highley; Simon Olpin; Christopher J McDermott; Pamela J Shaw; Janine Kirby
Journal:  Neuropathol Appl Neurobiol       Date:  2015-02       Impact factor: 8.090

8.  Seeking homeostasis: temporal trends in respiration, oxidation, and calcium in SOD1 G93A Amyotrophic Lateral Sclerosis mice.

Authors:  Cameron W Irvin; Renaid B Kim; Cassie S Mitchell
Journal:  Front Cell Neurosci       Date:  2015-07-01       Impact factor: 5.505

9.  Recent advances in amyotrophic lateral sclerosis research: perspectives for personalized clinical application.

Authors:  Chen Benkler; Daniel Offen; Eldad Melamed; Lana Kupershmidt; Tamar Amit; Silvia Mandel; Moussa B H Youdim; Orly Weinreb
Journal:  EPMA J       Date:  2010-06-29       Impact factor: 6.543

Review 10.  ALS and oxidative stress: the neurovascular scenario.

Authors:  Akshay Anand; Keshav Thakur; Pawan Kumar Gupta
Journal:  Oxid Med Cell Longev       Date:  2013-12-03       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.